BioTuesdays

Tag - BDRX

Biodexa Pharmaceuticals Logo
Developments

FDA fast tracks Biodexa’s eRapa in FAP

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA...

February 10, 2025
Biodexa Pharmaceuticals Logo
Executive Moves

Biodexa names Dr. Gary A. Shangold as CMO

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the appointment of Dr. Gary A. Shangold as chief medical officer (CMO), effective immediately. The company stated that Dr. Shangold brings extensive experience across...

January 22, 2025